The Pink Sheet’s Cathy Kelly takes a look at the Institute of Clinical and Economic Review’s recent announcement of a pilot aimed at boosting transparency in its drug assessment reviews.
ICER announced the pilot at the end of March.
The pilot, ICER says, will deliver to manufacturers the opportunity to analyze executable versions of draft cost-effectiveness models.
Click here to read Kelly’s story on Pink Sheet. (Paid subscription required)